Reason for request
Reassessment of medicines containing methylphenidate in attention deficit hyperactivity disorder in response to the instruction from the Directorate-General for Health.
Clinical Benefit
| Substantial |
The actual benefit of QUASYM LP proprietary products is substantial in the context of the overall therapeutic management of ADHD in children aged 6 years old and over when psychological, educational and social management alone prove insufficient. |
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
m6vetwuyezG0VA49
